Cargando…

Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity

Observational studies suggest outpatient metformin use is associated with reduced mortality from coronavirus disease‐2019 (COVID‐19). Metformin is known to decrease interleukin‐6 and tumor‐necrosis factor‐α, which appear to contribute to morbidity in COVID‐19. We sought to understand whether outpati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bramante, Carolyn T., Buse, John, Tamaritz, Leonardo, Palacio, Ana, Cohen, Ken, Vojta, Deneen, Liebovitz, David, Mitchell, Nia, Nicklas, Jacinda, Lingvay, Ildiko, Clark, Jeanne M., Aronne, Louis J., Anderson, Erik, Usher, Michael, Demmer, Ryan, Melton, Genevieve B., Ingraham, Nicholas, Tignanelli, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013587/ https://www.ncbi.nlm.nih.gov/pubmed/33580540 http://dx.doi.org/10.1002/jmv.26873

Ejemplares similares

Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit
por: Ibrahim, Sherehan, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.
por: Bramante, Carolyn T., et al.
Publicado: (2020)

68 Metformin prevents the diagnosis of Long Covid in phase 3 trial of early treatment.
por: Bramante, Carolyn, et al.
Publicado: (2023)

Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19
por: Bramante, Carolyn T., et al.
Publicado: (2020)

Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
por: Bramante, Carolyn T, et al.
Publicado: (2021)

Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
por: Bramante, Carolyn T., et al.
Publicado: (2022)

We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
por: Dutta, Nirjhar, et al.
Publicado: (2021)

Strategies used for the COVID-OUT decentralized trial of outpatient treatment of SARS-CoV-2
por: Avula, Nandini, et al.
Publicado: (2023)

Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms
por: Bramante, Carolyn T, et al.
Publicado: (2022)

Racial and Ethnic Disparities in Hospital Admissions from COVID-19: Determining the Impact of Neighborhood Deprivation and Primary Language
por: Ingraham, Nicholas E., et al.
Publicado: (2021)

A 12-hospital prospective evaluation of a clinical decision support prognostic algorithm based on logistic regression as a form of machine learning to facilitate decision making for patients with suspected COVID-19
por: Lupei, Monica I., et al.
Publicado: (2022)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease
por: Tignanelli, Christopher J., et al.
Publicado: (2021)

Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial
por: Bramante, Carolyn T, et al.
Publicado: (2023)

Responding to COVID-19 Through Interhospital Resource Coordination: A Mixed-Methods Evaluation
por: Usher, Michael G., et al.
Publicado: (2022)

Evaluation of an Intrahospital Telemedicine Program for Patients Admitted With COVID-19: Mixed Methods Study
por: Legler, Sean, et al.
Publicado: (2021)

Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients
por: Hozayen, Sameh M., et al.
Publicado: (2021)

Fact Versus Science Fiction: Fighting Coronavirus Disease 2019 Requires the Wisdom to Know the Difference
por: Ingraham, Nicholas E., et al.
Publicado: (2020)

Predictors of discharge disposition and mortality following hospitalization with SARS-CoV-2 infection
por: Ikramuddin, Farha, et al.
Publicado: (2023)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Barriers to and Facilitators for Acceptance of Comprehensive Clinical Decision Support System–Driven Care Maps for Patients With Thoracic Trauma: Interview Study Among Health Care Providers and Nurses
por: Jones, Emma K, et al.
Publicado: (2022)

Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles
por: Lusczek, Elizabeth R., et al.
Publicado: (2021)

Validation of a Proprietary Deterioration Index Model and Performance in Hospitalized Adults
por: Byrd, Thomas F., et al.
Publicado: (2023)

A randomized comparative effectiveness trial of using cable television to deliver diabetes prevention programming
por: Ackermann, Ronald T, et al.
Publicado: (2014)

Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women
por: Leng, Weiling, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Proteomic pathways associated with developing severe disease for patients with COVID-19: A biologic analysis of data from two multicenter randomized controlled trials encompassing 13 U.S. hospitals
por: Samorodnitsky, Sarah, et al.
Publicado: (2023)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Response to Comment on: Harrison et al. β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy. Diabetes Care 2012;35:1406–1412
por: Harrison, Lindsay B., et al.
Publicado: (2013)

Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome
por: Xing, Chuan, et al.
Publicado: (2022)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

A fast, resource efficient, and reliable rule-based system for COVID-19 symptom identification
por: Sahoo, Himanshu S, et al.
Publicado: (2021)

Rapid Improvement in Diabetes After Gastric Bypass Surgery: Is it the diet or surgery?
por: Lingvay, Ildiko, et al.
Publicado: (2013)

Chronic Pancreatitis Associated With a Variant of CFTR Gene Treated With Total Pancreatectomy and Autologous Islet Cell Transplantation
por: Agarwal, Shubham, et al.
Publicado: (2023)

A Prospective Observational Study to Investigate Performance of a Chest X-ray Artificial Intelligence Diagnostic Support Tool Across 12 U.S. Hospitals
por: Sun, Ju, et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

RF16 | PSUN177 Predictors of Postpartum Depressive Symptoms in Women with Recent GDM
por: Dias, Jennifer, et al.
Publicado: (2022)

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
por: Almandoz, Jaime P., et al.
Publicado: (2020)

Performance of a Chest Radiograph AI Diagnostic Tool for COVID-19: A Prospective Observational Study
por: Sun, Ju, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_764pajg68juit69fj5onsp0l7m